Your browser doesn't support javascript.
loading
Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease.
Marras, Theodore K; Mirsaeidi, Mehdi; Vinnard, Christopher; Chan, Edward D; Eagle, Gina; Zhang, Raymond; Wang, Ping; Zhang, Quanwu.
Afiliação
  • Marras TK; Department of Medicine, University Health Network and Mount Sinai Hospital , Toronto , ON , Canada.
  • Mirsaeidi M; Department of Medicine, University of Toronto , Toronto , ON , Canada.
  • Vinnard C; Pulmonary and Critical Care, University of Miami , Coral Gables , FL , USA.
  • Chan ED; Public Health Research Institute, Rutgers, The State University of New Jersey , Newark , NJ , USA.
  • Eagle G; Rocky Mountain Regional Veterans Affairs Medical Center , Aurora , CO , USA.
  • Zhang R; National Jewish Health , Denver , CO , USA.
  • Wang P; Insmed Incorporated , Bridgewater , NJ , USA.
  • Zhang Q; Orbis Data Solutions , Woburn , MA , USA.
J Med Econ ; 22(11): 1126-1133, 2019 Nov.
Article em En | MEDLINE | ID: mdl-31094592
ABSTRACT

Background:

The prevalence of nontuberculous mycobacterial lung disease (NTMLD) in the US has increased; however, data characterizing the associated healthcare utilization and expenditure at the national level are limited.

Objective:

To examine associations between economic outcomes and the use of anti-Mycobacterium avium complex (MAC) guidelines-based treatment (GBT) for newly-diagnosed NTMLD in a US national managed care claims database (Optum® Clinformatics® Data Mart).

Methods:

NTMLD was defined as having ≥2 claims for NTMLD (ICD-9 031.0; ICD-10 A31.0) on separate occasions ≥30 days apart (between 2007 and 2016). The cohort included patients insured continuously over a period of at least 36 months (12 months before initial NTMLD diagnostic claim and for the subsequent 24 months). Treatment was classified as GBT (consistent with American Thoracic Society/Infectious Diseases Society of America guidelines), non-GBT, or untreated. All-cause hospitalization rates and total healthcare expenditures at Year 2 were assessed as outcomes of the treatment prescribed in Year 1 after NTMLD diagnosis.

Results:

A total of 1,039 patients met study criteria for NTMLD (GBT, n = 294; non-GBT, n = 298; untreated, n = 447). After adjustment for baseline characteristics, GBT was associated with a significantly lower all-cause hospitalization risk vs non-GBT (odds ratio [OR] = 0.53; 95% CI = 0.33-0.85, p = 0.008), and vs being untreated (OR = 0.57; 95% CI = 0.35-0.91, p = 0.020). Adjusted total healthcare expenditure in Year 2 with GBT ($69,691) was lower than that with non-GBT ($77,624) with a difference of -$7,933 (95% CI = -$14,968 to -$899; p = 0.03).

Conclusions:

Patients with NTMLD in a US managed care claims database who were prescribed GBT had lower hospitalization risk than those who were prescribed non-GBT or were untreated. GBT was associated with lower total healthcare expenditure compared with non-GBT.
Assuntos
Palavras-chave

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Estado_mercado_regulacao / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Macrolídeos / Infecções por Mycobacterium não Tuberculosas / Antituberculosos Tipo de estudo: Guideline / Health_economic_evaluation / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Med Econ Assunto da revista: SERVICOS DE SAUDE Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Estado_mercado_regulacao / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Macrolídeos / Infecções por Mycobacterium não Tuberculosas / Antituberculosos Tipo de estudo: Guideline / Health_economic_evaluation / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Med Econ Assunto da revista: SERVICOS DE SAUDE Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Canadá